HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, March 29, 2019 (Pharmacist's Briefing) -- Varied study design and methodology make it difficult to assess real-world trends in adherence and persistence in use of biologics among U.S. adults with inflammatory bowel disease (IBD), according to a review published online March 14 in the Journal of Clinical Pharmacy and Therapeutics.
Shahnaz Khan, M.P.H., from RTI Health Solutions in Research Triangle Park, North Carolina, and colleagues conducted a systematic literature review to assess rates of adherence, persistence, switching, and dose escalations with biologics used to treat IBD in the United States.
The researchers found that the 41 included studies (published from 2012 to 2017) varied greatly in methodology, data sources, population studied, follow-up time, and end point definitions, thus preventing meaningful comparisons across studies. For the studies using a medication possession rate threshold of <80 or <86 percent, between 38 and 77 percent of patients were nonadherent to biologics. In six studies, up to 25 percent of patients discontinued medication within the first three months, while 7 to 65 percent discontinued by 12 months in 13 studies. In addition, in six studies, the switch rate to another biologic ranged from 4.5 to 20 percent among patients who initiated an index biologic. Only four studies reported dose escalations, which ranged from 8 to 35 percent of patients within the first year of therapy.
"Our findings suggest that real-world biologic use may be suboptimal and indicate new therapies and/or additional patient support may be needed," the authors write.
The authors disclosed financial ties to Janssen Scientific Affairs, which funded the study.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Read this Next
Other Trending Articles